Last reviewed · How we verify

adjuvant chemotherapy with 5-FU associated with oxaliplatin

University of Sao Paulo General Hospital · Phase 1 active Small molecule Quality 0/100

adjuvant chemotherapy with 5-FU associated with oxaliplatin is a Small molecule drug developed by University of Sao Paulo General Hospital. It is currently in Phase 1 development.

At a glance

Generic nameadjuvant chemotherapy with 5-FU associated with oxaliplatin
SponsorUniversity of Sao Paulo General Hospital
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about adjuvant chemotherapy with 5-FU associated with oxaliplatin

What is adjuvant chemotherapy with 5-FU associated with oxaliplatin?

adjuvant chemotherapy with 5-FU associated with oxaliplatin is a Small molecule drug developed by University of Sao Paulo General Hospital.

Who makes adjuvant chemotherapy with 5-FU associated with oxaliplatin?

adjuvant chemotherapy with 5-FU associated with oxaliplatin is developed by University of Sao Paulo General Hospital (see full University of Sao Paulo General Hospital pipeline at /company/university-of-sao-paulo-general-hospital).

What development phase is adjuvant chemotherapy with 5-FU associated with oxaliplatin in?

adjuvant chemotherapy with 5-FU associated with oxaliplatin is in Phase 1.

Related